Pharmacogenetic stimulation of cholinergic pedunculopontine neurons reverses motor deficits in a rat model of Parkinson\u27s disease by Pienaar IS et al.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This work is licensed under a Creative Commons Attribution 4.0 International License 
 
 
Newcastle University ePrints - eprint.ncl.ac.uk 
 
Pienaar IS, Gartside SE, Sharma P, DePaola V, Gretenkord S, Withers D, Elson 
JL, Dexter DT. Pharmacogenetic stimulation of cholinergic pedunculopontine 
neurons reverses motor deficits in a rat model of Parkinson's disease. 
Molecular Neurodegeneration 2015, 10, 47. 
Copyright: 
© 2015 Pienaar et al.  
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, 
distribution, and reproduction in any medium, provided you give appropriate credit to the original 
author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were 
made. The Creative Commons Public Domain Dedication waiver 
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, 
unless otherwise stated.  
DOI link to article: 
http://dx.doi.org/10.1186/s13024-015-0044-5 
Date deposited:   
16/11/2015 
  
Pienaar et al. Molecular Neurodegeneration  (2015) 10:47 
DOI 10.1186/s13024-015-0044-5RESEARCH ARTICLE Open AccessPharmacogenetic stimulation of
cholinergic pedunculopontine neurons
reverses motor deficits in a rat model
of Parkinson’s disease
Ilse S. Pienaar1,2*, Sarah E. Gartside3, Puneet Sharma1, Vincenzo De Paola4, Sabine Gretenkord3, Dominic Withers4,
Joanna L. Elson5,6 and David T. Dexter1Abstract
Background: Patients with advanced Parkinson's disease (PD) often present with axial symptoms, including
postural- and gait difficulties that respond poorly to dopaminergic agents. Although deep brain stimulation (DBS) of
a highly heterogeneous brain structure, the pedunculopontine nucleus (PPN), improves such symptoms, the
underlying neuronal substrate responsible for the clinical benefits remains largely unknown, thus hampering
optimization of DBS interventions. Choline acetyltransferase (ChAT)::Cre+ transgenic rats were sham-lesioned or
rendered parkinsonian through intranigral, unihemispheric stereotaxic administration of the ubiquitin-proteasomal
system inhibitor, lactacystin, combined with designer receptors exclusively activated by designer drugs (DREADD),
to activate the cholinergic neurons of the nucleus tegmenti pedunculopontine (PPTg), the rat equivalent of the
human PPN. We have previously shown that the lactacystin rat model accurately reflects aspects of PD, including a
partial loss of PPTg cholinergic neurons, similar to what is seen in the post-mortem brains of advanced PD patients.
Results: In this manuscript, we show that transient activation of the remaining PPTg cholinergic neurons in the
lactacystin rat model of PD, via peripheral administration of the cognate DREADD ligand, clozapine-N-oxide (CNO),
dramatically improved motor symptoms, as was assessed by behavioral tests that measured postural instability, gait,
sensorimotor integration, forelimb akinesia and general motor activity. In vivo electrophysiological recordings
revealed increased spiking activity of PPTg putative cholinergic neurons during CNO-induced activation. c-Fos
expression in DREADD overexpressed ChAT-immunopositive (ChAT+) neurons of the PPTg was also increased by
CNO administration, consistent with upregulated neuronal activation in this defined neuronal population.
Conclusions: Overall, these findings provide evidence that functional modulation of PPN cholinergic neurons
alleviates parkinsonian motor symptoms.
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The pedunculopontine nucleus (PPN), located in the dor-
sal tegmentum of the midbrain and upper pons, regulates
aspects of cognition, sleep architecture, motivation, re-
ward and locomotion [1, 2], potentially via ascending and
descending, afferent and efferent connections to many* Correspondence: i.pienaar@imperial.ac.uk
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(http://creativecommons.org/publicdomain/zebrain regions [3]. Studies reported a neuronal loss in
the PPN of patients with Parkinson’s disease (PD) [4, 5]
and in the most common atypical parkinsonian syn-
drome, progressive supranuclear palsy [4, 6]. This neur-
onal loss principally affects cholinergic neurons and may
underlie several of the motor abnormalities seen in PD
patients. Experimental evidence for this was provided by
the selective destruction of the pedunculopontine cholin-
ergic subpopulation in rats [7] and also in macaques [8],
through an intra-pedunculopontine infusion of a diph-
theria toxin (Dtx) conjugated to the peptide Urotensin IIis distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
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urotensin-II receptors that are expressed only by cho-
linergic neurons in this region. Dtx::UII induces a grad-
ual cholinergic-specific cell death by inhibiting the
synthesis of choline transporter [9]. Following lesion
formation in the rats, no effect was seen on execution
of individual motor actions; however, impairments
emerged when the demands of the task increased, i.e.,
during an acrobatic locomotor task (accelerating
rotarod) [7]. This result mimicked that reported from
the primate study, where the lesion induced no changes
in the levels of baseline locomotion; however, the ani-
mals displayed significant changes in gait and posture
when they were assessed in a guided and trained semi-
bipedal walking task [8].
Although no single genetic-based/toxin-induced ani-
mal model of PD perfectly recapitulates all neuropatho-
logical characteristics and clinical symptoms of the
human disorder [10], recent results have highlighted
the potential of the lactacystin rat model for studying
neuropathological mechanisms underlying PD [11]. In
rats receiving a unilateral injection of the irreversible
ubiquitin-proteasomal system inhibitor, lactacystin, into
the substantia nigra pars compacta (SNc), we recently
reported a loss of cholinergic neurons in the nucleus
tegmenti pedunculopontine (PPTg), the rodent equiva-
lent of the human PPN [12], which at 5 weeks following
the lesion, resembles the level of neuronal loss observed
in advanced human PD [11]. The toxin was shown to
affect non-cholinergic neurons in this nucleus also,
which mimics observations made in post-mortem PPN
tissue from PD-affected patients [5, 13]. This includes
recent findings [5], which revealed that alpha-synuclein
(αSYN) overexpression (resembling Lewy body path-
ology) affects both cholinergic and non-cholinergic
neurons in the PPN of post-mortem PD-affected brains
as well as in the PPTg of lactacystin-lesioned rats. In
line with this, a loss of both neuronal types was observed
in the PD cohort, although non-cholinergic neurons were
less impacted upon than the cholinergic population [5].
The pathological alterations, concomitant with nigrostria-
tal deficits and PD-related motor abnormalities seen in
the lactacystin rat model of PD [11, 13] strongly supports
the notion that a unilateral injection of lactacystin in rats
represents a useful experimental tool by which to investi-
gate the impact of PPN cholinergic deficits in PD, over
that of more traditional experimental models of PD. This
includes 6-hydroxydopamine (6-OHDA) lesioned rats,
which failed to induce the PPTg cholinergic cell loss seen
in human PD patients [14].
Deep brain stimulation (DBS) of the PPN (PPN-DBS)
improves Levodopa-unresponsive postural instability
and gait abnormality in PD patients [15–17]. Moro and
colleagues [18] presented the first report of the effects ofunilateral PPN-DBS in advanced PD cases, which were
assessed in a double-blinded manner. The authors re-
ported that patients reported a significant reduction in
the frequency of falls during both the ON and OFF
stimulation conditions, compared to pre-surgical levels.
This improvement was seen at 3 months and persisted
until assessment was repeated at 12 months post-
surgery. Certain gait parameters showed improvement at
3 months following surgery; however, this effect did not
persist until the repeat assessment at 12 months post-
surgery. No other major or subjective motor differences
were seen during either the ON or OFF stimulation as-
sessment conditions at 3 or 12 months of continuous
stimulation. Importantly, the study found that no signifi-
cant permanent adverse events were induced by the
chronic stimulation of the PPN region at 1 year follow-
ing the surgical procedure. Taken together, although the
study suffers from being based on a small cohort (n = 6),
with a relatively short follow-up period, the study
highlighted the potential of PPN-DBS to prevent falls
resulting from gait and postural disturbances.
In other recent work, Welter and colleagues [19] con-
ducted a double-blind cross-over, randomized trial of
PPN-DBS on PD patients. Although similarly powered
as the study by Moro and others [18], the study reported
a significant improvement in anticipatory postural ad-
justments and double-stance duration, but not the
length and speed of the first step. Moreover, the inter-
vention alleviated parkinsonian akinesia, while combined
PPN-DBS and levodopa treatment produced a significant
decrease in freezing episodes. Quality of life also im-
proved significantly with PPN-DBS.
Further support that PPN-DBS could be clinically
effective was gained from studies performed on 1-
methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-le-
sioned rhesus macaques that showed akinesia [20].
The study found that in these MPTP-induced parkin-
sonian animals, unilateral low frequency stimulation
of the PPN led to significantly increased levels of
motor activity, without inducing abnormal involuntary
movements as a side-effect to the treatment. In other
work by the same group, it was shown that stimula-
tion of the PPN in addition to Levodopa treatment of
MPTP-induced parkinsonian monkeys increased ani-
mals’ motor activity significantly more than Levodopa
treatment alone [21]. However, both the human PPN
and the rat PPTg are highly heterogeneous structures,
containing cholinergic [22, 23], gamma-aminobutyric
acid (GABA)ergic [5, 24], glycinergic [5] and gluta-
matergic neurons [24]. PPN-DBS stimulates all cell
types indiscriminately, leaving it impossible to identify
which neuronal subtype underlies clinical improve-
ments. To understand the possible therapeutic effects
of stimulating PPTg cholinergic neurons on a range
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model of PD, we utilised designer receptors exclusively
activated by designer drugs (DREADD) [25] to select-
ively depolarize cholinergic neurons in the PPTg of
sham- and toxin-lesioned rats. A viral vector, adeno-
associated virus (AAV) containing the floxed muscar-
inic G protein-coupled receptor, hM3Dq [26, 27] was
stereotaxically infused into the PPTg of choline acetyl-
transferase (ChAT)::Cre rats, where all cholinergic neu-
rons express Cre-recombinase [28], thus restricting
hM3Dq expression to cholinergic neurons. Neurons
expressing hM3Dq were stimulated by peripherally ad-
ministering the synthetic ligand, clozapine-N-oxide
(CNO) [26]. An overview of the entire experimental
procedures followed is provided in Additional file 1:
Figure S1. Effects were examined in four treatment
groups: SNc-lactacystin + PPTg-DREADD (L + D), SNc-
lactacystin-vehicle + PPTg-DREADD (V + D) rats, con-
trasting with lesioned and sham-lesioned animals that
had received a control viral vector (AAV-channelrho-
dopsin2 (hChR2)) in the PPTg: SNc-lactacystin-vehicle
+ PPTg-control virus (V + CV) and SNc-lactacystin +
PPTg-control virus (L + CV).
Results
Vector-mediated expression of hM3Dq and ChR2 is
restricted to Cre expressing ChAT-immunopositive neurons
of the PPTg
Stereotaxic administration of AAV-hM3Dq-mCherry
(Fig. 1a) into the PPTg of ChAT::Cre rats (Fig. 1b) re-
sulted in the mCherry signal being seen exclusively in
the plasma membrane and some axons of PPTg ChAT-
immunopositive (ChAT+) neurons (Fig. 1c, d). Similarly,
hChR2 administered into the PPTg of ChAT::Cre rats re-
sulted in exclusive detection of yellow fluorescent pro-
tein (eYFP), a fluorescent marker for cells expressing
ChR2, in ChAT+ PPTg neurons (Fig. 1e, f ). hM3Dq-
mCherry co-expressed PPTg ChAT+ neurons by >70 %
(V + D: 74 ± 2 %, L + D: 72 ± 1 %, p = 0.41, NS, Fig. 1g).
Similarly, the proportion of neurons co-expressing
ChR2-eYFP and ChAT in the PPTg was >70 % in sham
and lesioned rats (V + CV: 73 ± 3 %, L + CV: 75 ± 1 %, p =
0.67, NS, Fig. 1g). The high level of cholinergic neuronal
transduction efficiency seen in all rat groups, confirmed
our ability to selectively target the constructs to PPTg cho-
linergic neuron using this method. Moreover, ChAT+
PPTg neurons co-expressing either hM3Dq-mCherry or
hChR2-eYFP, displayed typical cholinergic neuronal
morphology, presenting with medium to large somata.
The large neurons had 3–6 primary dendrites of a fusi-
form, triangular or multipolar shape, while medium-sized
neurons appeared round or oval, with only 2–3 dendrites,
in accordance with previous reports [29, 30]. Furthermore,
the particular DREADD made use of here, expressed onthe plasma membrane of the transduced target neurons
[26]. Taken together, this result indicates that the strategy
employed serves as an effective one by which to restrict
hM3Dq and ChR2 expression to Cre expressing ChAT+
neurons in the PPTg of rats.
In rats administered CNO, hM3Dq-, but not ChR2 transduced
ChAT+ PPTg neurons show c-Fos immunoreactivity,
restricted to the stereotaxically injected hemisphere
The transcription factor c-Fos is an indirect marker of
neuronal activity, which upregulates in response to in-
creased neuronal activity [31]. No c-Fos expression was
seen in the PPTg in unlesioned hemispheres in any ex-
perimental group, thus we restricted analyses to the le-
sioned (and viral vector infused) side. +CNO resulted in
high c-Fos + overlap with hM3Dq + PPTg neurons (V +D:
69.37 ± 3.33 % overlap between ChAT+ and c-Fos + neu-
rons, L +D: 72.52 ± 2.48 % overlap (Fig. 2a). ChAT-c-Fos
co-expression was ten-fold lower in hM3Dq-receiving rats
when CNO wash-out was allowed prior to brain tissue
collection (V +D: 4.35 ± 0.72 % and L +D: 6.53 ± 1.70 %,
***p <0.0001, Fig. 2a).
Conversely, during + CNO, in both PPTg-CV rat groups,
% c-Fos-hM3Dq +was very low (V +CV: 5.15 ± 1.06 % and
L + CV: 7.3 ± 2.03 %, Fig. 2b). However, during + CNO, the
% overlap for V +CV (3.94 ± 1.15 %) and L + CV (8.37 ±
1.87 %) were similar to the ones for V +D –CNO and L +
D -CNO (Fig. 2b, c).
Stereological cell counts validated the expected levels of
neuronal loss in the lactacystin-lesioned rats
Each experimental group (L + D, V + D; L + CV and V +
CV; n = 12/group) was divided into rats that underwent
CNO wash-out (n = 6) before brains were removed for
analyses and those sacrificed soon (2–3 h) after receiving
CNO (n = 6), when CNO could still be present. Follow-
ing unbiased stereological estimation, statistical analyses
revealed that systemically-remaining CNO didn’t exert a
statistically significant effect on the interhemispheric
counts of tyrosine hydroxylase immunopositve (TH+)
neurons in any of the rat groups, which prompted us to
combine the + CNO and –CNO stereological datasets
for each of the experimental groups. The stereologically
determined numerical densities of SNpc dopaminergic
neurons revealed a substantial loss of TH+ SNpc neu-
rons in lactacystin-lesioned rats (left, injected side: 6,348
± 442 (L + D); 6,644 ± 624 (L + CV); right, non-injected
side: 11,437 ± 334 (L + D); 11,544 ± 446 (L + CV)). On
the other hand, stereological cell counts of the total
number of SNpc dopaminergic neurons compared
favourably between the two hemispheres in the 2 groups
of sham-lesioned control rats (left, injected side:
11,515 ± 621 (V +D); 11,462 ± 435 (V +CV); right, non-
injected side: 11,537 ± 504 (V +D); 11,622 ± 651 (V +CV)).
Fig. 1 (See legend on next page.)
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Fig. 1 DREADD design and stereotaxic delivery results in high ChAT-DREADD+ neuronal expression within the rat PPTg. a Schematic showing the
Cre-dependent AAV containing mutant hM3Dq. Upon expression, hM3Dq-mCherry and ChR2-eYFP is inverted to enable transcription from the EF-1a
promoter. b The location for unilateral stereotaxic injection of either constructs into the PPTg of Chat::Cre-transgenic rats, along with either lactacystin
or lactacystin vehicle into the unilateral SNc. c High magnification confocal photomicrographs show strong ChAT- immunofluorescence
signaling for individual cell bodies that overlap considerably with mCherry-tagged hM3Dq, expressed in the plasma membrane. The intensity of the
immunofluorescence signal for ChAT (green) significantly surpassed the intrinsic brightness of expressed hM3Dq (red), the latter that was induced
through viral vector-mediated transduction. Co-expressing neurons appear mainly green, due to the strong immunosignal of the applied secondary
antibody for ChAT, but with some yellow labelling. d A low magnification image shows the PPTg resident cholinergic neurons (green), interspersed
with cholinergic neurons co-expressing (yellow) mCherry-tagged hM3Dq. e High magnification confocal images show red labelled ChAT+ neurons
co-expressing (yellow/orange) eYFP-tagged hChR2. f A low power confocal image shows the high degree of co-expressing ChAT+ (red) and yellow
labelled hChR2 PPTg neurons. In the case of both hM3Dq and hChR2, viral vector-mediated expression was limited to PPTg ChAT+ neurons. However,
some variance in viral vector-mediated expression was seen, especially in the case of ChAT-hChR2, with some individual ChAT+ cells that expressed
the gene construct to a lesser extent (visible as a lower fluorescence intensity, such neurons being indicated by a red asterisk in (e), left panel) than
other transduced cholinergic cells. High power images were taken with a 20×, air-immersion objective lens, while low power images were
captured with a 63× oil-immersion objective lens. Arrowheads point to ChAT+ neurons that did (yellow) and did not (white) express the respective
virally transduced constructs. Scale bars: 50 μm (c, e); 100 μm (d, f). g The degree of overlap between ChAT+ (green) and hM3Dq + (red) neurons for
the V +D (n= 12) and L +D rats (n= 12) and the overlap between ChAT+ (red) and hChR2+ (yellow) neurons for V + CV (n= 12) and L + CV rats (n= 12)
revealed that dual expression of the viral vector-ChAT+ PPTg neurons exceeded 70 %, relative to all ChAT+ PPTg neurons. This demonstrates
that our approach using Cre-mediated recombination to selectively express DREADD within PPN cholinergic neurons resulted in high
transduction efficiency
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differences between the injected left and non-injected right
SNpcs of: 44.29 ± 1.78 % (L +D), 0.19 ± 0.57 % (V +D),
42.39 ± 1.21 % (L +CV) and 1.21 ± 1.63 % (V +CV). Specif-
ically, L +D rats’ interhemispheric % cell loss was strik-
ingly increased compared to V + D rats (***p <0.0001,
Fig. 3a, b). Erats compared to V + CV ones (***p
<0.0001, Fig. 3a, b). A comparison of the interhemi-
spheric cell loss of TH+ neurons between the
lactacystin-lesioned (L + D and L + CV) and sham-
lesioned control animals (V + D and V + CV) revealed
a significant loss of TH+ neurons in the SNpc on the
lactacystin-injected brain hemispheric side, compared
to the non-lesioned SNpc (***p <0.0001; Fig. 3a, b).
Data sets were combined for analysing cholinergic ste-
reology data also, as no significant difference was seen
between the +0CNO and –CNO data sets in any of the
experimental groups. In V + D and V + CV rats, stereo-
logical cell counts of the mean total number of PPTg
cholinergic neurons, identified as being ChAT+ cells,
were similar between the sham-injected SNpc (V + D:
3,108 ± 49; V + CV: 3,097 ± 40) and right, non-injected
SNpc (V + D: 3,081 ± 57; V + CV: 3,111 ± 54, p = 0.62,
NS), translating to a percentage difference of −1.27 ±
2.5 % for V + D rats and 0.42 ± 2.19 % for V + CV ones
(Fig. 4a). These data correlate with previous reports of
unihemispheric PPTg cholinergic cell counts made in
rats [11, 14]. In contrast, lesioned rats (L + D and L +
CV) revealed a significant loss of cholinergic neurons on
the left, lesioned side (L + D: 1,878 ± 66; L + CV: 1,963 ±
38), compared to the intact opposite hemisphere (L + D:
2,987 ± 26; L + CV: 3,064 ± 28), translating to a loss of
36.94 ± 2.53 % for L + D rats and 35.85 ± 1.41 % for L +
CV rats, the interhemispheric neuronal loss for thesetwo groups being marginal (p = 0.71, NS, Fig. 4a). Com-
parison of interhemispheric % cell loss between V + D
and L + D animals revealed a significant loss of choliner-
gic neurons (***p <0.0001, Fig. 4a), validating our previ-
ous findings [11]. When comparing V + CV and L + CV
rats, the difference was again statistically significant
(***p <0.0001, Fig. 4a).
Previous work revealed a higher concentration of cho-
linergic neurons in the most rostral segments of the
PPTg than was seen in the caudal half of the nucleus
[23], in non-lesioned rats. Along with data revealing an
opposite trend for GABAergic neurons in the rat PPTg
[23], this suggests that functional subregions exist within
the PPTg. We validated whether a similar cholinergic
density distribution was seen in the sham-lesioned
ChAT::Cre rats (V +D and V +CV) and whether the PPTg
cholinergic density decrease seen in lactacystin-lesioned
rats (L +D and L +CV) extended from the most rostral
(closest to the SNc, comprising the site of toxin injection)
through to the most caudal PPTg sections [11].
Changing densities across the different rostro-caudal
segments were similar in all groups (Fig. 4b, c), with the
total number of cholinergic cell counts increasing as the
distance away from the SNr increased. We followed the
accepted means of defining the borders of the PPTg ac-
cording to the cholinergic neurons; hence the increased
density partially reflects the increasing area of the PPTg,
as it extends caudally. The main effect of ‘treatment’ on
cell density, proved statistically non-significant (p = 0.076,
NS). However, the other main effect, ‘progressive distance
away from the SNc’ (S1-7) on cholinergic cell density, was
significant (*p <0.05, Fig. 4b, c) in both groups of lesioned
rats, compared to their relative control group. No statisti-
cally significant differences were detected. No interaction
Fig. 2 Injection of CNO induces c-fos immunoreactivity in PPTg ChAT+ neurons of rats expressing Cre-dependent AAV-hM3Dq-mCherry. In
ChAT::Cre rats where hM3Dq (red) was expressed unilaterally in the PPTg and when brains were obtained within 90 min of administering
CNO, c-Fos immunoreactivity (green nucleic stain) overlapped with the hM3Dq signal, confirming that CNO stimulates hM3Dq-expressing
PPN neurons. a c-Fos-expressing cell counts revealed relatively high expression in the ipsilateral but not the contralateral PPTg of V + D
and L + D rats (n = 12/group). However, c-Fos signalling levels in rats that underwent a CNO wash-out phase lasting ~48 h, prior to sacrifice and brain
collection, detected minimal hM3D+ neurons co-expressing c-Fos. b In both PPTg-CV rat groups (n = 12/group), ChAT-c-Fos neuronal overlap
was nearly undetectable, when measured either at + CNO or -CNO. c Representative fluorescent microscopy images of contralateral and ipsilateral
PPTg c-Fos fluorescence seen in the same brain section but in the different experimental groups. Merged images are shown in the right panels, with
yellow indicating co-localisation. Magnification: ×20, scale bar: 25 μm. Mean ± SEM, *p <0.05
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pair-wise comparison of the mean value for each section,
in relation to each rat group was performed which showedno statistically significant differences. Photomicrographs
(Fig. 4d) reveal the loss of cholinergic neurons along the
rostro-caudal extent of the PPTg.
Fig. 3 Lactacystin lesioning induces a nigral dopaminergic lesion that closely resembles clinical PD. a Stereological quantification of TH+
neurons in the SNc on the lactacystin-lesioned side reveals a near 50 % loss of TH+ neurons, when compared to the same hemispheric
side of sham-lesioned rats (n = 12/group). Mean ± SEM, ***p <0.001. b Representative Bright field images using a 4×/0.10 NA air objective
taken of TH+ neurons in coronal brain sections containing the SNc at 5 weeks post-surgery for all experimental groups. Scale bar: 200 μm
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lactacystin-lesioned rats recovered to pre-toxin performance
scores obtained in the postural instability test
No significant differences were found for the ipsilateral
(non-impaired) forelimb, when considering either the fac-
tors ‘treatment group’ or ‘time-point’. Results were then
compared between use of the contralateral (impaired)
forelimb at baseline and at 5 weeks post-surgery during –
CNO vs. +CNO. For V +D rats, there was no significant
decline by the contralateral forelimb between baseline and
5 weeks post-surgery during –CNO (p = 0.69, NS).
However, in this group there was a subtle increase in
stepping distance by the contralateral forelimb during
+ CNO (*p = 0.034), compared to baseline perform-
ance (Fig. 5a). For L + D rats, there was a pronounced
decline in contralateral forelimb use during –CNO
compared to baseline (***p <0.0001). However, during
+ CNO the stepping distances made by the contralateral
forelimb were comparable to that at baseline (p = 0.33,
NS; Fig. 5a). In V + CV rats, the stepping distances taken
by the contralateral forelimb remained consistent betweenmeasures taken at baseline and during –CNO (p = 0.51,
NS) and –CNO vs. +CNO (p = 0.42, NS). For L + CV rats,
effective use by the contralateral forelimb was dramatically
reduced during –CNO, compared to baseline performance
(***p <0.0001). In this group, there remained a highly sig-
nificant impairment in stepping ability by the contralateral
forelimb when animals were reassessed during + CNO,
compared to baseline performance (***p <0.0001; Fig. 5a).
There was no change in contralateral forelimb placement
performance from –CNO to + CNO at the 5 week post-
surgery testing phase (p = 0.67, NS).
Following CNO administration, significant recovery was
also seen in forelimb akinesia in the lactacystin-lesioned
rats stereotaxically co-infused with hM3Dq into the PPTg
Use of the contralateral forelimb increased in all do-
mains tested, when comparing + CNO to –CNO stages,
but improvement was most evident in wall exploration.
The level of “wall placement” by L + D rats showed sig-
nificantly increased asymmetry between baseline and –
CNO (***p <0.0001; Fig. 5b). However, asymmetry scores
Fig. 4 (See legend on next page.)
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Fig. 4 Lactacystin-induced PPTg cholinergic lesions resemble PPN cholinergic neuronal loss seen in post-mortem human PD patients. a Stereological
cell counts confirmed a decrease in interhemispheric ChAT+ cholinergic neurons of the PPTg in rats that had received an intranigral unihemispheric
injection of lactacystin (L + D and L + CV, n = 12), compared to sham-lesioned rats (V + D and V + CV, n = 12). V + D vs. L + D rats, ***p <0.001; V + CV
vs. L + CV, ***p <0.001. A depiction of cholinergic cell density throughout the rostro-caudal extent of the nucleus reveals that in rats that
had been lesioned (L + D and L + CV), cholinergic cell density was decreased throughout the entire rostro-caudal extent of the nucleus,
compared to sham-lesioned rats (V + D and V + CV), with neuronal loss noted in even the most caudal parts of the PPTg. Bars depict
mean values ± SEM of cholinergic neuronal densities for b V + D compared to L + D rats and c V + CV compared to L + CV rats. d Low-magnification
photomicrographs of representative PPTgs in a V + D and L + D rat illustrates how the loss of cholinergic neurons was maintained across
the rostro-caudal extent of the PPTg in L + D rats. Scale bar: 200 μm
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preceding –CNO stage (***p <0.0001), although the
scores did not completely return to baseline level, with a
significant difference seen between baseline and + CNO
(*p = 0.014). In contrast, V + D rats’ asymmetry scores
did not differ significantly between different test stages
(Fig. 5b). For L + CV rats, a significant deterioration in
symmetry was seen between baseline and –CNO
(***p <0.0001), showing no improvement during CNO
(p = 0.81, NS). Lastly, asymmetry scores remained
constant for V + CV rats throughout the different
testing conditions, with limb use remaining highly
symmetrical (Fig. 5b).
“Serial-stepping” with each forelimb was relatively rare
in intact rats, but L + D rats showed increased asym-
metry from baseline to –CNO (***p <0.0001; Fig. 5c).
During the + CNO condition, symmetry was enhanced
significantly (***p <0.0001), compared to –CNO. Per-
formance scores recorded between baseline and + CNO
were comparable (p = 0.09, NS; Fig. 5c), contrasting with
the V + D group, whose performance remained constant
throughout all testing stages, similar to that seen for the
V + CV rats. However, for L + CV rats, a significant in-
crease in asymmetry (***p <0.0001; Fig. 5c) was seen
when comparing baseline to –CNO scores. Performance
between –CNO and + CNO continued to decline, al-
though this did not reach statistical significance (p =
0.07, NS; Fig. 5c).Contralateral forelimb placement showed near complete
recovery in the vibrissae-evoked forelimb placement test
during hM3Dq-mediated stimulation of PPTg cholinergic
neurons in lactacystin-lesioned rats
Correct placements by the ipsilateral forelimb (driven by
the non-lesioned cerebral hemisphere) were unaffected
by CNO in all of the groups, restricting analysis to the
affected contralateral forelimb placements. V + D rats
showed no failed responses across any testing sessions
(Fig. 5d). L + D rats showed dramatic symptom reversal
during + CNO compared to –CNO (***p <0.0001),
returning to near-baseline levels (Fig. 5d). V + CV ani-
mals performed similarly to V + D rats, while scores ob-
tained by L + CV rats showed severe decline when ratswere assessed either at + CNO or –CNO, compared to
baseline (Fig. 5d).
Toxin injected, hM3Dq PPTg stereotaxically infused
animals showed a number of significant functional gains
post CNO administration in the open field test
Table 1 shows the results of all behavioral parameters
analysed during the open field test. Compared to base-
line performance, no parameters were affected in V +
CV rats during –CNO or + CNO. Although no signifi-
cant alteration was noted for V + D rats from baseline to
–CNO, during + CNO a significant behavioral enhance-
ment was observed for most measures, including dis-
tance covered during the trial (Fig. 5e). During –CNO,
L + D and L + CV rats revealed a decreased performance
in all but one parameter. However, CNO given to L + D
rats significantly improved these deficits, with several
returning or even exceeding baseline values, whilst CNO
failed to reverse any deficits induced by SNc lesioning in
L + CV rats. Analyses of the number of ipsilateral rota-
tions displayed by the various groups did not reveal the
same clear behavioral profile observed for all other activ-
ity measures, with no significant change observed be-
tween baseline and –CNO or during + CNO, for any of
the experimental groups.
Increased spiking activity of PPTg putative cholinergic
neurons seen during CNO-induced activation in
hM3Dq-receiving rats and confirmed absence of increased
PPTg spike rate activity in rats PPTg-infused with hChR2
We recorded and analysed a total of 89 putative cholin-
ergic PPTg neurons from 18 animals (1–10 neurons/ani-
mal) from all groups. For statistical analysis V + CV and
L + CV rats were combined. Examination of coronal
PPTg-containing sections revealed that the electrode
marked with DiI was correctly placed within the PPTg
(Fig. 6a, top and bottom).
The PPTg neurons displayed heterogeneous electro-
physiological characteristics. For the majority (72/89) of
neurons, the extracellularly recorded action potential
displayed a large negative deflection, often followed by a
pronounced positive deflection (after hyperpolarization),
amounting to approximately a third of the maximal ampli-
tude of the negative deflection (Fig. 6b, top left). In some
Fig. 5 (See legend on next page.)
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Fig. 5 Stimulating PPTg cholinergic neurons drives functional recovery in lesioned rats. a Unilateral excitation of PPTg cholinergic improve
scores in the PIT in L + D rats (n = 12) during + CNO, compared to baseline. A subtle increase in stepping distance by the contralateral
forelimb was also seen post CNO in V + D rats (*p = 0.034, n = 12). Vertical cylinder test results reveal that PPTg cholinergic-specific stimulation rescued
the contralesional limb deficit seen in L + D rats during b wall placement and c wall "hopping”. d Percentage unsuccessful contralateral
forelimb placements by rats following stimulation of ipsilateral vibrissae over ten trials. Placement was unsuccessful for nearly all trials in
the L + D and L + CV treated rats during -CNO, whereas responses by V + D and V + CV treated rats were near perfect. e Representative
examples illustrating the distance covered (m) by rats of the different experimental groups showing how, at 5 weeks following the
surgery, L + D rats covered significantly less distance in the Open Field arena when measures were taken at -CNO, compared to + CNO.
Although the majority of parameters assessed in the Open Field showed complete recovery of function for L + D rats during + CNO in
relation to baseline values, the rats of this group did not completely recover to pre-surgical performance levels in terms of ‘distance
covered’ (see Table 1). However, a significantly improved effect was seen during + CNO compared to -CNO. In contrast, L + CV rats’
performance decreased between baseline and -CNO, while rats were similarly impaired during + CNO. V + CV rats displayed constant
patterns of behaviour throughout all testing phases. Bars depict mean values ± SEM
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tial was predominantly a positive deflection, which was
generally wider than the negative spikes (Fig. 6b, top
right). For the remaining 3/89 neurons the extracellularly
recorded action potential was a bipolar positive–negative
deflection (Fig. 6b, bottom left). During –CNO, the major-
ity of neurons fired relatively regularly (Fig. 6c, top), a mi-
nority of neurons fired irregularly (Fig. 6, middle), while
others exhibited distinct phasic activity for at least part of
the recording period (Fig. 6, bottom). Firing rates ranged
from 0.25–220.27 Hz (Fig. 6d), with the median fir-
ing rates (and interquartile range) for the groups
that were as follows: V + D, 5.47 Hz (1.50–14.5 Hz);
L + D, 7.50 Hz (3.84–16.09); V + CV-L + CV, 7.34 Hz
(3.21–21.75 Hz; Fig. 6d). No significant difference
was seen between the groups in terms of firing rates
during –CNO phase (p = 0.23, NS). In the V + D and
L + D rats, but not V + CV-L + CV rats, +CNO in-
creased the firing rate in a number of neurons above
their spike rate during –CNO (Fig. 6e).
In L + D rats, from –CNO to + CNO phases, 4/23 neu-
rons more than doubled their firing rate, whilst 7/23
neurons decreased their firing rate >50 %. The remain-
der of neurons (12/23) maintained their firing rate
within 50-200 % of the –CNO rate. In the V + D group,
similar proportions of CNO-responsive neurons were
found. Thus 9/38 neurons more than doubled their fir-
ing rate during + CNO, while 8/38 neurons decreased
their firing rate >50 %. The remainder of neurons main-
tained their firing rate within 50–200 % of the rate re-
corded during –CNO. In the combined V + CV and L +
CV groups, none of the 28 recorded neurons doubled
their firing rate after CNO. In contrast, 11/28 neurons
decreased their firing rate by >50 %, while the remaining
17 neurons maintained firing between 50 and 200 % of
the –CNO rate.
There was a significant relationship between ex-
perimental group and the number of cells that
showed increased firing, no change and decreased
firing after CNO (*p = 0.042). The most notabledifference was between V + D and L + D rats and the
combined V + CV-L + CV groups as to number of neurons
showing a marked increase in firing during + CNO (4/23,
9/38 and 0/28, respectively).
Table 2 shows the basal characteristics of putative cho-
linergic PPTg neurons post-CNO. No neurons with very
high firing rate during –CNO increased their firing rate
after CNO. CNO-responsive neurons were heteroge-
neous with respect to their basal firing rate and action
potential shape. The CNO response (expressed as a per-
centage of baseline) varied, ranging from 281–1,899 % in
L + D rats and 206–2,348 % in V + D rats (Fig. 6f ). In all
neurons which showed firing rate increases following
CNO administration, the increased firing rate was ac-
companied by increased regularity, defined as decreased
CV ISI (*p ≤ 0.05, Fig. 6g, h).Discussion
In this study, selective PPTg cholinergic neuronal stimu-
lation utilising expression of an excitatory DREADD
which was activated by the selective agonist CNO, re-
sulted in marked reversal of motor deficits in the lacta-
cystin rat model of PD, suggesting that PPTg cholinergic
neurons play a vital role in maintaining motor function
in dopamine-deficient rats. To confirm that CNO acti-
vates PPTg cholinergic neurons, we assessed expression
of the immediate early gene, c-Fos, in the PPTg of the
rats. c-Fos has been shown to be activated through Gs-
mediated signaling events, thus it serves as marker of
neuronal activity [32].c-Fos immunoreactity has been
used by others as an effective tool by which to validate
whether peripheral administration of CNO induces in-
creased intracellular signaling within target neurons lo-
cating to restricted parts of the brain, where DREADD
had been expressed [33–35]. Approximately two hours
after administering CNO, when c-Fos protein levels are
elevated [27], large numbers of c-Fos + neurons over-
lapped with PPTg hM3Dq + ones in both V + D and L +
D rats. This contrasted with animals from the same
Table 1 Open field performance for L + D (a), V + D (b), L + CV (c) and V + CV (d) rats. Hemi-lesioned rats (L + D and L + CV) were
severely impaired in all principal motor behaviours and in aspects of complex behaviour, when comparing baseline performance
with that at -CNO. When L + D rats were reassessed during + CNO, performance values indicated complete recovery
A L + D Baseline 5 weeks post-surgery
-CNO +CNO
Principally motor behavior Ambulation count (N) 8.92 (±0.54) 5.25 (±0.43) 12.67 (±0.85)
Average speed (m/s) 0.47 (±0.02) 0.29 (±0.02) 0.48 (±0.02)
Maximum speed (m/s) 0.74 (±0.02) 0.48 (±0.02) 0.75 (±0.02)
Time spent mobile (s) 212.13 (±5.16) 193.28 (±2.68) 211.88 (±3.30)
Distance covered (m) 11.55 (±0.35) 4.66 (±0.39) 6.65 (±0.47
Rotational behavior Contralateral rotations 4.25 (±0.55) 3.58 (±0.42) 2.75 (±0.28)
Ipsilateral rotations 3.17 (±0.41) 3.08 (±0.4) 3.08 (±0.48)
Complex behavior Time spent rearing (s) 51.33 (±2.39) 59.58 (±1.65) 69.58 (±1.72)
Time spent performing fine motor activity (s) 73.42 (±1.73) 50.50 (±3.61) 73.08 (±2.83)
B V + D Baseline 5 weeks post-surgery
-CNO +CNO
Principally motor behavior Ambulation count (N) 9.25 (±0.59) 8.83 (±0.59) 12.83 (±0.76)
Average speed (m/s) 0.46 (±0.04) 0.47 (±0.03) 0.48 (±0.02)
Maximum speed (m/s) 0.72 (±0.3) 0.73 (±0.02) 0.72 (±0.03)
Time spent mobile (s) 213.40 (±4.5) 211.86 (±3.44) 218.48 (±3.36)
Distance covered (m) 10.26 (±0.39) 10.17 (±0.32) 11.57 (±0.57)
Rotational behavior Contralateral rotations 3.50 (±0.39) 1.67 (±0.31) 4.42 (±0.31)
Ipsilateral rotations 3.25 (±0.41) 3.00 (±0.46) 3.25 (±0.46)
Complex behavior Time spent rearing (s) 53.67 (±1.67) 54.33 (±3.0) 73.25 (±1.58)
Time spent performing fine motor activity (s) 75.58 (±2.14) 76.25 (2.48) 78.67 (±2.61)
C L + CV Baseline 5 weeks post-surgery
-CNO +CNO
Principally motor behavior Ambulation count (N) 10.58 (±0.74) 4.83 (±0.39) 4.92 (±0.38)
Average speed (m/s) 0.51 (±0.04) 0.28 (±0.02) 0.27 (±0.03)
Maximum speed (m/s) 0.62 (±0.02) 0.45 (±0.02) 0.43 (±0.03)
Time spent mobile (s) 209.30 (±5.40) 191.70 (±6.06) 190.90 (±5.74)
Distance covered (m) 11.01 (±0.53) 5.12 (±0.53) 5.05 (±0.51)
Rotational behavior Contralateral rotations 4.17 (±0.58) 1.58 (±0.42) 1.50 (±0.40)
Ipsilateral rotations 3.00 (±0.44) 3.25 (±0.39) 3.33 (±0.40)
Complex behavior Time spent rearing (s) 48.17 (±1.89) 46.42 (±2.08) 45.42 (±1.97)
Time spent performing fine motor activity (s) 69.00 (±2.48) 47.67 (±4.39) 43.83 (±5.14)
D V + CV Baseline 5 weeks post-surgery
-CNO +CNO
Principally motor behavior Ambulation count (N) 9.67 (±0.66) 9.83 (±0.63) 10.33 (±0.41)
Average speed (m/s) 0.52 (±0.04) 0.52 (±0.02) 0.52 (±0.02)
Maximum speed (m/s) 0.69 (±0.04) 1.15 (±0.43) 0.71 (±0.03)
Time spent mobile (s) 216.17 (±4.31) 217.15 (±3.77) 217.03 (±3.23)
Distance covered (m) 10.99 (±0.52) 11.07 (±0,43) 11.28 (±0.43)
Rotational behavior Contralateral rotations 3.50 (±0.59) 3.75 (±0.45) 3.33 (±0.54)
Ipsilateral rotations 2.83 (±0.47) 3.00 (±0.44) 3.00 (±0.33)
Complex behavior Time spent rearing (s) 50.83 (±2.09) 48.42 (±1.93) 49.25 (±2.08)
Time spent performing fine motor activity (s) 77.42 (±1.69) 78.33 (±1.61) 74.83 (±2.29)
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Fig. 6 In vivo functional assessment of DREADD activity. a Correct electrode placement, marked by red DiI for in vivo PPTg electrophysiology
recordings (a, top) shows ChAT+ neurons (green) co-localizing with hM3Dq + ones (red). (a, bottom) shows ChAT+ neurons (red) co-localizing
with hChR2+ (yellow) ones. Arrows indicate the electrode tips. Scale bar: 20 μm. b Average extracellularly recorded action potential waveforms
showing example units with predominantly negative deflections (b, left) with (blue) and without (red) a later positive deflection, (b, centre) a
predominantly positive deflection and (b, right) a bipolar positive–negative deflection. Voltage deflections were normalized to the maximum or
minimum deflection (100 %). c Example traces of neurons firing (c, top) regularly, (c, middle) less regularly, and (c, bottom) phasically, during -CNO.
d A box and whisker plot of firing rates during -CNO for all groups. Data are median (line), interquartile range (box) and 10th - 90th percentiles
(whiskers). e Example rate meter histogram depicting a PPTg neuron from an L + D rat, with large increase in firing rate during + CNO compared
to -CNO. f Example rasters for two neurons responding to + CNO with increased firing rate and clearly increased regularity of firing during + CNO
(lower part of each pair) compared to -CNO (upper part of each pair). An expanded time-base during +CNO facilitates comparison of firing
patterns. g Average firing rates during + CNO, expressed as a percentage of the rate during -CNO for all groups. Each dot represents an individual
neuron. h CV ISI during + CNO and -CNO for neurons which increased firing rate by >100 %. Differences were highly significant (**p <0.01). Each dot
pair (joined by a line) represents an individual neuron
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exceeded the nine hours that CNO remains systemically
active [27], before animal sacrifice and immunohisto-
chemical processing, where we observed minimal c-Fos
expression overlap with PPTg hM3Dq + neurons. Fur-
thermore, CNO failed to induce any c-Fos signal in
PPTg hChR2+ neurons in animals stereotaxically injected
with the control viral vector (V +CV and L +CV). This
confirms that in vivo CNO is specific to DREADD recep-
tors, producing transient and alterations of G-protein
dependent signaling in the DREADD-transduced target
neurons.
In vivo electrophysiology revealed that CNO adminis-
tration increased the firing rate of PPTg putative cholin-
ergic neurons in animals receiving DREADD, but not
vector-mediated hChR2 transduced ones. Post-hoc spike
data analyses revealed that in all groups, presumed cho-
linergic neurons excited by CNO were heterogeneous
with respect to action potential shape, firing rate and
pattern during –CNO. This is consistent with other re-
ports that PPTg cholinergic neurons cannot reliably beTable 2 Putative cholinergic PPTg neurons’ basal firing and actio
categorized post-hoc by their responses to CNO, which was defi
compared to the rate during -CNO phase), ‘no change’ (during +
or ‘decrease’ (during + CNO, firing rate was ≤ 50 % compared to
that the voltage deflection occurred upwards, negative, meaning
where voltage deflections occurred both up- and downwards
Group Response type n AP shap
Negativ
V + D Excitation 9 (24 %) 9
No response 24 (63 %) 20
Inhibition 5 (13 %) 4
L + D Excitation 4 (17 %) 2
No response 12 (52 %) 11
Inhibition 7 (30 %) 6
Abbreviations: AP Action potentialdistinguished from non-cholinergic neurons by action
potential shape, firing rate or -pattern [36].
Previous studies made efforts to classify neurons in
the PPTg in terms of their physiological properties. Stud-
ies principally using in vitro preparations had previously
defined four types of PPTg neurons based on their elec-
trophysiological membrane properties [37–39]. Type I
neurons were shown to exhibit low-threshold Ca2+
spikes (LTS), while Type II neurons displayed a fast tran-
sient outward potassium current (A-current). Type II
neurons were also shown to display repetitive and rhyth-
mic spontaneous firing with a frequency of 5–15 spikes/s
[39]. Type III PPTg neurons are characterized by both
LTS and A-current, while Type IV PPTg neurons exhibit
neither LTS nor A-current. Reports on the neurochemical
phenotype of neurons belonging to these classification cri-
teria vary, with some studies using combined biocytin la-
belling and ChAT immunohistochemistry showing that
50–60 % of Type 2 and Type 3 neurons are cholinergic,
whereas Type 1 and Type 4 neurons were deemed non-
cholinergic [37, 39]. On the other hand, Kim and othersn potential waveforms in V + D and L + D rats. Neurons were
ned as ‘increase’ (firing rate during + CNO phase was ≥ 200 %
CNO, firing rate was 50–200 % compared to during -CNO)
during -CNO). The AP shape is classified as positive, meaning
that the voltage deflection occurred downwards, or bipolar,
e Basal firing Hz
(Median and range)e Positive Bipolar
0 0 5.75 Hz (0.3–24.2)
3 1 5.473 (0.4–49.3)
1 0 3.13 (0.4–31.6)
2 0 4.09 (0.3–8.8)
1 0 10.84 (0.6–83.4)
1 0 7.08 (2.3–62.3)
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with nicotinamide adenine dinucleotide phosphatedia-
phorase (NADPH-d), a reliable marker for mesopontine
cholinergic neurons [41], with results indicating that
66.7 % of Type 2 neurons and 88.2 % of Type 3 neurons
are cholinergic, while the remainder of the Type 2 and
Type 3 neurons were non-cholinergic. A small minority
of non-cholinergic neurons was classified as being Type
IV neurons. No Type I neurons were observed in this
study. Therefore, a consistent correlation between the
proposed classification system and the neurotransmitter
phenotype of recorded PPTg neurons displaying Type I,
II, III or IV properties remains to be confirmed, particu-
larly in in vivo preparations. Moreover, the classification
scheme only allows for distinguishing between cholinergic
and non-cholinergic neurons in general, with neuro-
physiological profiles correlating to a single Type, which
were revealed to consist of “mixed” populations, contain-
ing both cholinergic and non-cholinergic neurons [37, 42].
A study by Zhang and colleagues [43] found that the
majority of presumed cholinergic and non-cholinergic
neurons in the unlesioned rat PPTg show a regular firing
pattern in normal rats, while in rats that had received an
SNc lesion of 6-OHDA, an increased percentage of pre-
sumed non-cholinergic neurons exhibited an irregular
firing pattern, while the firing pattern of presumed cho-
linergic neurons remained similar to those recorded in
normal rats. Moreover, the study found that lesioning of
the nigrostriatal pathway induced an increase in firing
rate of both cholinergic and non-cholinergic neurons in
the rat PPTg.
We saw a range of firing patterns in CNO-responsive
neurons, ranging from irregular and tonic to regular, as
well as those showing distinct phasic activity. However,
all neurons which showed a large increase in firing rate
also showed a decrease in the CV ISI during the + CNO
phase. In L + D rats during –CNO, we observed no
spontaneous increases in the firing activity of putative
cholinergic PPTg neurons. This contrasts with Breit and
others [44], who reported that in intranigrally 6-OHDA
lesioned rats, PPTg neurons’ spontaneous activity was in-
creased; a result that was subsequently confirmed in
studies by Jeon and others [45], hence wise supporting
the postulation that the pedunculopontine nucleus is in-
volved in the pathophysiology of parkinsonism. Further
interesting findings reported by Breit and others [44] in-
cluded that ibotenic acid-induced lesioning of the sub-
thalamic nucleus (STN) induced a reduction in the
firing rate of the PPTg in normal rats, while normalizing
the firing rate in rats that had also received an intrani-
gral 6-OHDA lesion, thereby suggesting that the PPTg is
under major control of the STN.
During –CNO, neither action potential shape nor fir-
ing rate differed between groups. In V + D and L + Drats, a fifth to a quarter of the recorded neurons showed
a large increase in firing rate following CNO administra-
tion, contrasting to rats microinfused with the control
virus in the PPTg, where no recorded neurons showed a
similar response to CNO. Hence we can ascribe the in-
creased firing rate to activation of hM3Dq by CNO.
Moreover since our histological data showed h3MDq ex-
pression exclusively in ChAT+ neurons, we can presume
that the neurons that showed this large excitatory re-
sponse to CNO to have been cholinergic.
PPTg cholinergic neuronal firing rate became both
faster and more regular during + CNO, suggesting that
this activity pattern is sufficient for rescuing motor def-
icits resulting from lactacystin-induced cell loss, synap-
tic disruptions and circuit disturbances. MacLaren and
coleagues [7] demonstrated that the PPTg acts as part
of a rapid action selection system, integrating sensory
information into motor output. However, in PD there is
abnormal processing of sensory information resulting
in failure to generate and execute movement [46]. We
used the vibrissae-evoked forelimb placement test to
assess sensorimotor integration across the midline.
PPTg cholinergic neuronal stimulation in lesioned rats
totally negated failures in forelimb placements follow-
ing whisker stimulation, but only in L + D and not in L
+ CV rats. Previous work suggested that this may be
due to modulation of the thalamus and cerebral cortex
by PPTg cholinergic neurons [47]. Taken together, the
c-Fos immunoreactivity and in vivo electrophysiology
data serve to validate that CNO successfully activated
the PPTg target neurons, to provide a plausible neural
substrate for motor function recovery seen in the par-
kinsonian rats.
Posture- or gait disabilities form major deficits in PD
patients and contribute to risk of falling, with evidence
indicating that PPN cholinergic dysfunction underlies
these difficulties [8]. However, in the study performed
by Karachi and others [8], only indirect evidence was
given that PPN cholinergic neurons underlie these be-
havioral deficits, as the investigators lesioned the PPN
using Dtx::UII, with recent work revealing that the
toxin induces PPN GABAergic and glutamatergic neur-
onal loss in addition to PPN cholinergic neuron loss
[48]. The authors noted that the loss of non-cholinergic
neurons in the PPN of Dtx::UII lesioned macaques may
have been secondary to the primary loss of PPTg cho-
linergic neurons, but that it is also possible that the
Dtx:UII conjugate exerts a degree of toxic action on
non-cholinergic neurons, even when it does not bind to
the urotensin-II receptor.
Although no single study has given direct evidence that
dysfunction affecting the PPN’s cholinergic population
underlie postural instability in PD patients, the fact that
dopaminergic medication does not fully ameliorate gait
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neurons play a prominent contributing role in sustaining
gait [49]. In one study, Bohnen and colleagues [50] con-
ducted an in vivo positron emission tomography (PET)
study and showed that PD patients with a history of
falls have significantly decreased thalamic (i.e., PPN)
cholinergic innervation compared with PD patients
classified as non-fallers, whereas no difference was de-
tected in the degree of nigrostriatal dopaminergic
denervation between these two groups. Moreover,
Rochester and others [51], using short-latency afferent
inhibition as a putative marker of cholinergic function
in cortical and subcortical cholinergic systems [52],
showed that cholinergic dysfunction plays an import-
ant early role in gait abnormalities in PD, and hence
represents a potential therapeutic target.
In the current study, the performance of L + D, but
not L + CV rats in the PIT was markedly improved dur-
ing + CNO, supporting a role for PPTg cholinergic neu-
rons in gait control. PPN-DBS for alleviating postural
instability and gait disturbances [18] is still regarded as
experimental, while studies reported so far provide only
indirect evidence for the role of cholinergic neurons in
gait and postural control. Our data provide direct evi-
dence that targeting PPN cholinergic neurons alleviates
parkinsonian symptoms. A tentative, but speculative ex-
planation for the improved behavioral effects seen in the
L + D rats during + CNO may be that PPTg cholinergic
neurons exert stimulatory effects on neurons in the PPTg’s
output nuclei, such as the SNc and the STN [53–55], with
SNc dopaminergic neurons that undergoes substantial de-
generation in PD and in animal models of the disease [56],
while the STN exhibits hyperactivity following such
chronic dopamine loss [57, 58]. The current study lays
the foundation for future work to explore whether the
behavioral recovery seen here is due to a synaptic inter-
action between remaining neurons in the PPTg and
those in the SNc, or between neurons in the PPTg and
those in the STN.
Hemi-lesioned rats display akinesia (poverty or no
control over voluntary movements) in the contralesional
forelimb during the “cylinder” test [59], the functional
deficit correlating with the dopaminergic lesion size [60]
and also shows sensitivity to anti-parkinsonian medica-
tion [61]. Hence, our finding that PPTg cholinergic
stimulation alleviates akinesia in lesioned rats agrees
with others who hypothesised that PPN cholinergic de-
terioration is directly involved in akinesia, as evidenced
by the loss of PPN cholinergics in the akinetic syndrome,
progressive supranuclear palsy [4, 62].
Our current results also reveal that PPTg cholinergic
function appear critical for general motor behavior in an
open field enclosure. Such behaviors have a cognitive
component and it is therefore not surprising thatchanges were noted in PPTg stimulated rats, as the PPN
holds extensive reciprocal connections with corticostria-
tal systems with bearing on cognition and emotional re-
activity [1, 2].
Future experiments should determine whether any of the
motor symptoms shown by intra-nigral lactacystin-lesioned
rats show improved metrics, such as a lateralization im-
provement, in response to the immediate metabolic
precursor of dopamine, levodopa and direct dopamine
agonists such as apomorphine. In this regard, work
by Nakagawa and others [63] revealed that levodopa
and apomorphine effectively ameliorated the motor
imbalance brought on by a single unihemispheric in-
jection of 6-OHDA into the medial forebrain bundle.
Similar experiments using the lactacystin rat model of
PD will significantly enhance understanding as to why
DBS of the PPN improves levodopa-unresponsive
motor symptoms in PD patients [15–17] and whether
this effect relies on a neuromodulatory action by the
PPN’s remaining cholinergic neurons on the midbrain
dopaminergic system.
Conclusions
Overall, the results presented in this study provide evi-
dence for a cholinergic-based mechanism for a range of
motor symptoms, including gait- and postural abnormal-
ities, similar to what is observed in advanced PD. In
addition, we demonstrate that transient cholinergic-
specific stimulation allows for a striking improvement in
motor scores in a realistic rodent model of PD. There-
fore, our observations may have an impact on ongoing
efforts for optimizing DBS-based therapeutic outcomes
in advanced PD patients whilst the minimizing side-
effect profile. Taken together, the work serves as a
proof-of-principle that similar studies for dissecting out
the relative functional contributions made in a cell
type-specific manner in brain targets such as the STN
[64], deemed promising for alleviating neurological or
neuropsychiatric deficits by means of electrical stimu-
lation, can be achieved using DREADD technology, if
applied to well-described animal models of neurode-
generative disease.
Methods
Drugs
CNO was obtained from Enzo Life Sciences, dissolved in
dimethyl sulfoxide (DMSO) and then diluted in 0.9 % saline
solution to yield a final DMSO concentration of 10 %, was
administered to all animals at a dose of 1 mg/kg. CNO ve-
hicle injections consisted of saline containing 10 % DMSO.
D-amphetamine sulphate was purchased from Sigma-
Aldrich and administered at a dose of 5 mg/kg,
dissolved in 0.9 % saline. All drugs were injected in-
traperitoneally (i.p.).
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For production of the DREADD, the hM3Dq coding se-
quence [27] with an mCherry c-terminal tag, was cloned
into a FLEX switch cre inducible AAV vector carrying
the elongation factor 1 alpha (EF1α) promoter (Fig. 1a).
The final vector (1.4 × 1013 genomic copies/ml) was se-
quence verified and then packaged with AAV2 serotype
coat proteins by Vector Biolabs (Philadelphia, USA).
An AAV viral construct (7.1 × 1012 genomic copies/
ml) with floxed inverted ChR2 (containing the H134R
mutation), which was fused in-frame with enhanced yel-
low fluorescent protein (eYFP) and driven by the EF1a
promoter, was serotyped with AAV5 coat proteins (Viral
Vector Core Facility, UNC, Chapel Hill, USA). Rats in-
fused into the PPTg with this construct controlled for
the DREADD virus injection, since hChR2(H134R)-eYFP
is activated optogenetically [65], but is unresponsive to
CNO. Aliquots of virus lots were stored at −80 °C until use.Animals and surgeries
Imperial College London’s ethics review panel approved
all experimental protocols. All animal experiments were
performed in accordance with the Animals (Scientific
Procedures) Act, 1986 (UK). Rats were housed socially
(2–3 animals per cage) and maintained on a 12 h light–
dark cycle (between 6:30 and 7:00 AM). Access to food
pellets and water was provided ad libitum.
Long-Evans ChAT::Cre hemizygous rats (Missouri
Mutant Mouse Regional Resource Centre, University
of Missouri, USA) were bred with Long-Evans wild-type
rats (Charles River Laboratories, Germany) to produce
Cre-positive offspring. At weaning age, ear punches were
collected from each rat from which genomic DNA was
extracted to genotype the Cre recombinase transgene
using a polymerase chain reaction. Only male rats were
used in all treatment protocols, as it is currently unknown
whether lactacystin lesions in rats induce sexually di-
morphic actions, as other neurotoxin-based animal
models of PD have been shown to produce [66]. The rats
were randomly assigned to one of 4 treatment groups,
namely L +D (n = 12), V +D (n = 12), L + CV (n = 12) and
V +CV (n = 12).
The ChAT::Cre rats were secured in a stereotaxic
frame in a flat skull position under anaesthesia (5 %
Isoflurane, IsoFlo®, Abbot Laboratories, UK; vaporised
into oxygen 1.5 L/min), whilst receiving analgesia
(Buprenorphine; Alstoe Animal Health, York, UK).
Bupivacaine (Taro, Ireland), locally administered to the
scalp, provided local anaesthesia. The skull was exposed
and a small burr hole was drilled through the cranium
with a dental drill above the left SNc. Lactacystin (4 μl of
2.5 μg/μl, Enzo Life Sciences, UK; 1 μl/min), dissolved in
sterile saline (pH 7.4), was delivered using the followingcoordinates: 5.2 mm anterior-posterior (AP), +2.4 mm
medio-lateral (ML) and −7.6 mm dorso-ventral (DV) [12],
from bregma, using a 10 μl Hamilton syringe. Sham-
lesioned rats received an equal volume of sterile saline
only. Saline and lactacystin groups were operated on in a
randomised manner, during the same surgical session.
Following the intra-nigral stereotaxic injection, the rats
were then infused with the viral construct (1.5 μl) into
the left PPTg (coordinates: −7.8 mm (AP), +1.8 mm
(ML), −7.0 μm (DV) [11, 13], at rate of 0.2 μl/min. The
needle was lowered a further 0.2 μm to deliver an add-
itional 1.5 μl, using a removable 32 gauge needle (7762–
05, Hamilton, Reno, USA). All infusions made were
driven by a microinjector syringe pump (11 Plus Elite,
Harvard Apparatus, Holliston, USA). The needle was left
in situ for 5 min before slowly retracting from the brain.
The skin incision was sutured (removed 7–10 days post-
surgery) and rats were left to recover.
Detailed behavioral procedures
All behavioral assessments were performed by an assessor
blind to the treatment condition of the animals. All ex-
perimental procedures were conducted during the light
portion of the light–dark cycle. Testing was performed at
baseline before surgery and repeated at 5 weeks post-
surgery, during which behavioral testing commenced
40 min after peripheral administration of CNO-vehicle
(−CNO), to compare to the results achieved by the same
rats and executing the same testing procedures when
CNO (+CNO) was injected into a rat and testing took
place 40 min later.
Amphetamine-induced rotation
To evaluate the extent of the dopaminergic lesion in the
SNpc of the rats lesioned with lactacystin, amphetamine-
induced ipsiversive rotation was assessed in all lactacystin-
lesioned rats (L + D and L +CV), at 3 weeks post-surgery.
Following an i.p. injection of the amphetamine solution,
rats were individually placed in a large bowl and the net
number of rotations made ipsilateral to the lesion was
counted over 30 min, beginning at 20 min after the am-
phetamine injection. Lesioned rats were included in the
study if amphetamine induced at least 7 rotations/min
ipsilateral rotations.
Open field
We measured rats’ activities when placed in a white Plexi-
glass open field arena (90 cm long × 90 cm wide × 60 cm
deep). ANY-Maze software (Stoelting ANY-Maze, Wood
Dale, USA) quantified parameters from digital camera re-
cordings (5 min/rat) to provide ambulation counts (N),
average speed (m/s), maximum speed (m/s), time spent
mobile (s) and distance covered (m), contralateral- and ip-
silateral rotations and time spent grooming (s).
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Unihemispheric administration of lactacystin produces
motor asymmetry, allowing comparison of the affected
and unaffected limbs. In the limb-use asymmetry (“cylin-
der”) test, a rat’s use of the ipsilateral (unimpaired),
contralateral (impaired) and both limbs for making con-
tact with the inner wall of the cylinder (wall placement)
and inner wall exploration (“serial-stepping”) after fully
rearing up, was assessed as described elsewhere [11, 59].
For baseline, −CNO and + CNO testing phases, we video
recorded 20 rears/rat.
Postural instability test
The postural instability test (PIT) [59] was performed by
holding a rat at 45° in a “wheelbarrow”-like position over a
sandpaper-covered surface. The tip of the rat's nose was
aligned with the zero line of a ruler. The experimenter re-
strained one forelimb against the animal's torso while
moving the animal forward over the planted forelimb until
making a step to regain its centre of gravity. The new pos-
ition of the nose tip was recorded. Three trials per fore-
limb were performed per testing session.
Vibrissae-evoked forelimb placement test
The vibrissae-induced forelimb placement test assesses
for sensorimotor integration across the midline [59].
Briefly, the animal was held by the torso and its vibrissae
brushed against the edge of a tabletop to elicit a forelimb
placing response from the ipsilateral limb. Ten trials per
side per test session were performed.
Animal sacrifice and brain tissue processing
Animals were anaesthetized with sodium pentobarbital
(60 mg/kg) before transcardial perfusion with 50 ml hepa-
rinized PBS (37 °C), followed by 4 % paraformaldehyde
(PFA). Brains were removed and post-fixed in 4 % PFA
overnight and then immersed in graded sucrose solutions
for ~48 h at 4 °C. Brains were snap-frozen in pre-chilled
isopentane, coronally sectioned (30 μm) with a cryostat
(Bright Instruments, UK), mounted onto slides (VWR
International, UK) and stored at −80 °C until processing.
hM3Dq- and ChR2 expression
The transduction efficiency of viral constructs within
ChAT+ PPTg neurons of ChAT-Cre rats was deter-
mined using immunofluorescence and confocal mi-
croscopy. Non-specific binding was blocked by incubating
with 5 % normal horse serum (Sigma-Aldrich) for
60 min at room temperature (RT) for slides stained
for hM3D-ChAT and with 5 % normal donkey serum
(Sigma-Aldrich) for ChR2-ChAT. Polyclonal goat anti-
ChAT primary antibody (1:100, AB144P, Millipore,
Temecula, USA) was applied overnight at 4 °C. For
staining the ChR2-ChAT neurons, the sections werewashed in PBS, before incubating for 2 h at RT with
Alexa Fluor 488-conjugated horse anti-goat IgG for
labelling hM3Dq-ChAT neurons and Alexa Fluor 594-
conjugated donkey anti-goat IgG secondary anti-
bodies, with both that were purchased from Vector
laboratories, Cambridge, UK. Dilutions of the primary
and secondary antibodies were made in PBS contain-
ing 0.3 % Triton X-100. Sections were washed in
PBS, before mounting them with coverslips with Pro-
Long Gold (Invitrogen, Paisley, UK).
Proportions of ChAT+ neurons overlapping with
hM3Dq-mCherry + ones and ChAT+ neurons that were
also eYFP+ (expressing ChR2) were determined in
double immunolabelled, serial cut PPTg sections, spaced
180 μm equidistant apart. Only the injected hemisphere
was analysed, using 4 sections/rat. Sections were imaged
in a single z-plane with a TCS SP5 II confocal laser scan-
ning microscope (Leica Microsystems, Wetzlar,
Germany), fitted with a Leica DFC 320 digital camera
and using a 40×/1.4 N.A. oil-immersion objective lens.
All ChAT+ cell bodies in areas where the mCherry or
eYFP fluorescence could be seen were imaged. An image
was taken of each ChAT+ neuron, producing 120–140
images/rat in the V + D and V + CV rats and 30–50 in L
+ D and L + CV rats. Co-transduction efficiency was de-
termined by analysing the images post-capture using
ImageJ v1.45 software (NIH). For ChAT-hM3Dq, the red
and green filters were minimized to identify cell bodies
that expressed only ChAT (green), mCherry (red) or
both. For the ChAT-hChR2 combination, filters were
minimized to identify cell bodies expressing only ChAT
(red), eYFP (yellow) or both.
Immunohistochemistry
For immunohistochemical labelling of ChAT+ PPTg
neurons and TH+ dopaminergic SNc neurons using 3,
3’-diaminobenzidine (DAB) chromogen, we followed our
previously described protocols [11]. Immunohistochemi-
cal controls were performed by omitting the primary
antibody. Coverslips were applied with DPX mounting
medium (Sigma-Aldrich), with sections mounted serially
and in a rostro-caudal direction.
Stereological cell counts
The stereology platform consisted of a computer-based ste-
reology software program (ImagePro, MediaCybernetics,
USA) attached to a Nikon Eclipse E800 microscope and a
3CCD camera (JVC Ltd., London, UK). Firstly, the areas of
interest (the SNc and PPTg) were delineated under a low
magnification view (2.5× air-immersion objective lens).
The computer software then created counting frames
(200 × 250 μm) that fell within the respective area of
interest (AOI). The SNc was delineated from the rest
of the brain based on anatomical landmarks and the
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plasmic TH immunoreactivity, with the cells forming
a dense population of neurons. The SNc was also dis-
tinguished from the other SN subnucleus, the sub-
stantia nigra pars reticulata (SNr), as well as the
ventral tegmental area (VTA) and the retrorubral
area, by referring to published guides on the anatom-
ical landmarks and regional variations in cell density,
orientation and morphological boundaries [12, 67].
On the other hand, the PPTg was recognised on the
ChAT-stained sections by the PPTg’s characteristic
wedge-like shape [11, 14]. Its rostral border consisted of
the SNr, with the PPN extending dorso-caudally towards
the lateral tip of the superior cerebellar peduncle, at an
angle of ~60° from a vertical line [23]. The perimeter of
the PPTg was defined as comprising the Ch5 cholinergic
neuronal population, regarded as synonymous with the
PPTg [22]. We distinguished the PPTg-Ch5 cell group
from cholinergic cell group Ch6, comprising the latero-
dorsal tegmental nucleus, that lies dorsal and caudal to
the neighboring PPTg. In this regard, laterodorsal tegmen-
tal nucleus was recognised as dorsally abutting the aqua-
duct, whilst its caudal extreme end is positioned between
the locus coeruleus and the fourth ventricle [12, 68].
Stereological estimates of the number of TH+ and
ChAT+ neurons were made in the lesioned and non-
lesioned brain hemispheres, comparing lactacystin-lesioned
rats to control animals (non-lesioned vs. non-lesioned brain
hemispheres for each group). Following immunohistologi-
cal processing of the SNc- and PPTg-containing sections,
these were mounted serially, in a rostro-caudal direction.
Every 6th section of the series of sections that contained the
AOI was analysed using an unbiased stereology approach
that makes use of the optical fractionator method, as previ-
ously described [69].
Cells were counted under a low power magnification
(20× air-immersion objective lens), by a single investigator
who was blinded to the animal treatment. The computer
software program allowed for automatic and random
movement between the sampling areas that included ap-
propriate “acceptance” and “forbidden” lines. The “forbid-
den line” rule was applied in the counting protocol, which
entailed that only neurons that fell within the sampling
area or were touching the “acceptance” line were included
in the overall count. In addition, a cell was only consid-
ered if the bottom of the cell was observed within the vol-
ume of the dissector (the height of the section thickness,
excluding a 2 μm thick guard zone at the top of the sec-
tion). The dimensions of the sampling grid were set at
120 × 120 × 5 μm (x, y, and z axes, respectively).
The total area of the counting frame, relative to the
area of the AOI gives the area sampling fraction (asf ).
The height sampling fraction (hsf ) was represented by
the height of the optical dissector, calculated by takingan average of 3 random points across the section, using
a microcator (Hedenhain, Germany), relative to the ac-
tual section thickness (30 μm). In addition, the section
sampling fraction (ssf ) was 1/6, representing every 6th
section throughout the AOI. Total cell estimates were
then calculated by using the formula: N = n(1/ssf )(1/
asf )(1/hsf ), where n equals the number of positive cells
counted. An estimate of the precision of the stereologi-
cal estimates derived at, termed the coefficient of error
[70], were calculated for all samples used, to yield a
value of 0.15 or less, whilst a mean coefficient of error of
less than 10 % was obtained for the estimates made
within each individual animal.
c-Fos immunofluorescence
Following the last behavior test, half the number of rats
per group were transcardially perfused with 4 % PFA,
while the remainder were allowed a CNO wash-out
phase (~48 h) before perfusion. To immunofluorescently
stain for c-Fos, 10 % normal goat serum was applied to
hM3Dq expressing PPTg sections and 10 % normal don-
key serum to hChR2 expressing ones, for 60 min at RT.
The primary antibody (1:100, anti-c-Fos rabbit poly-
clonal IgG; SC-52, Santa Cruz Biotechnology, Santa
Cruz, USA) was applied overnight (4 °C), followed by
secondary antibodies: Alexa Fluor 488-conjugated goat
anti-rabbit IgG (1:200, Invitrogen) for c-Fos-hM3Dq and
Alexa Fluor 594-conjugated donkey anti-rabbit IgG
(1:200, Invitrogen) for c-Fos-ChR2. Antibodies were di-
luted in Tris-buffered saline containing 0.3 % Triton X-
100. Sections were washed in PBS and coverslipped
using ProLong Gold mounting medium (Invitrogen). No
unwanted background was found in the corresponding
immunohistochemical negative controls with the omis-
sion of incubation with primary antibodies. Likewise, to
ensure that the secondary antibodies did not non-
specifically bind to certain cellular compartments, sec-
ondary control reactions were performed where the sec-
ondary antibody was omitted. This procedure produced
no fluorescent signal.
Contiguous, slightly overlapping individual images
(×40 magnification, oil, 1.4 NA) of PPTg cholinergic
neurons in each hemisphere were taken using a TCS
SP5 II confocal laser scanning microscope (Leica Micro-
systems, Wetzlar, Germany), fitted with a Leica DFC 320
digital camera and stitched together (Image-Pro Plus
software v5.1, Media Cybernetics, Bethesda, USA).
Image stacks (8 slices separated by 10 μm steps) were
gathered from three sections distanced 180 μm apart.
Cells were counted in alternate image slices to yield cell
numbers for three different positions along the z-axis.
The c-Fos, hM3Dq and ChR2 signals were counted sep-
arately, after which the individual signals were merged
and the number of c-Fos + neurons co-localising with
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cholinergic neurons were counted. Co-localization was
calculated by dividing the number of c-Fos–hM3Dq or
c-Fos–ChR2 co-positive cells by the number of hM3Dq
+ or ChR2 + cells, respectively.
In vivo electrophysiology
At five weeks following surgery, in vivo PPTg electro-
physiological recordings were made. Rats were anesthe-
tized with urethane (1.5–1.8 g/kg) and secured in a
stereotaxic frame. The skull was exposed and a hole was
drilled over the left PPTg using the same coordinates as
was used for delivering the DREADD or control virus. A
silicon electrode array with 16 iridium contacts, spaced
at 100 μm and in a linear formation (A1x16-10 mm-
100-177-A16, NeuroNexus Technologies, Ann Arbor,
USA) was then implanted perpendicularly to the dorsal
surface of the rat’s skull. Using a fine control hand-
driven micromanipulator, the tip of the recording elec-
trode was positioned at the most dorsal border of the
PPTg [12] and slowly advanced until a recording pos-
ition was found where a number of channels (a total
of 16 was available) showed spike discharges. The
probe was never descended to a depth exceeding the
reference coordinates given for the PPTg’s most ven-
tral edge (−7.8 mm), at this AV-ML coordinate [12].
The probe then remained in position throughout the
two recording stages. This consisted of an i.p. admin-
istration of CNO vehicle. At 40 min post-injection, the
neurons were recorded for 12 min. This was followed
by an i.p. injection of the CNO solution. Again, neur-
onal activity was recorded for 12 min, also at 40 min
post-injection. Both CNO vehicle and the CNO solu-
tion were administered at a dose of 1 mg/kg, similar
to that given for the various behavioral assessments.
Extracellular signals were amplified (×1000) and band-
pass filtered (150 Hz–9 kHz), using a PBX preamplifier
(Plexon, Dallas, USA), passed through Humbug filters
(Digitimer Research Instruments, Hertfordshire, UK)
and digitized (Micro 1401–3, Cambridge Electronic
Design, Cambridge, UK) at a sampling rate of either 16.7
or 20 kHz. Spiking activity was recorded and captured
on a PC using Spike2 software (v7.10b, Cambridge
Electronic Design). Following the recording session, the
rat was euthanized, perfused and the brain removed. To
histologically verify the recording site, the probe was
painted with red lipophilic fluorescent dye, DiI (Invitrogen).
Only the data of rats where immunofluorescent images
showed that the electrode had traversed the PPTg success-
fully was used in the analyses of the electrophysiological re-
cording data.
Spike sorting was performed manually using Offline
Sorter software (Plexon, Dallas, USA). For each recorded
channel, thresholds for spike detection were set manually.Waveforms passing the threshold were distinguished
using principal component analysis. Consistent and distin-
guishable waveforms were considered to be extracellularly
recorded action potentials from single units. For all well-
isolated units which fired spontaneously before ad-
ministering CNO, time stamp data were exported to
NeuroExplorer4 (Nex Technologies, Madison, USA).
Firing rate and the co-efficient of variation of the
interspike interval (CV ISI) was determined during
two 12 min periods: −CNO (commencing 40 min after ad-
ministering CNO vehicle) and + CNO (commencing
40 min after administering CNO).
Statistical analyses
The vibrissae-evoked forelimb placement test data was ana-
lysed using a Chi-square test. A two-way ANOVA, followed
by Tukey post-hoc testing compared ipsilateral to contralat-
eral hemispheric SNc TH+ and PPTg ChAT+ cell loss in
lesioned vs. sham-lesioned rats. A mixed design (or split-
plot) ANOVA was used for the PIT and cylinder test. For
analyzing the in vivo electrophysiology data sets, firing rates
of recorded PPTg neurons were analysed with a Kruskal–
Wallis test. The proportion of cells showing excitatory
responses in the four groups was assessed using contin-
gency table analysis (the Monte Carlo simulation option).
c-Fos expression data was analyzed using a one-way
ANOVA, followed by a Tukey post-hoc test. Data was ana-
lysed using Statistical Package for Social Sciences software
(v19, IBM). P-values were designated as: ***p <0.001, ex-
tremely significant; **p ≤ 0.01, highly significant; *p ≤ 0.05,
significant and p > 0.05, non-significant (NS). Graphical
data is expressed as the means ± standard error of the mean
(SEM) or median and interquartile range.
Additional file
Additional file 1: Figure S1. A schematic showing the sequential
protocol followed for the in vivo experiments conducted on the rats
during the +CNO and –CNO phases. (TIFF 2395 kb)
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